AR122262A1 - Subunidad s1 modificada de la proteína de espícula de coronavirus - Google Patents

Subunidad s1 modificada de la proteína de espícula de coronavirus

Info

Publication number
AR122262A1
AR122262A1 ARP200101291A ARP200101291A AR122262A1 AR 122262 A1 AR122262 A1 AR 122262A1 AR P200101291 A ARP200101291 A AR P200101291A AR P200101291 A ARP200101291 A AR P200101291A AR 122262 A1 AR122262 A1 AR 122262A1
Authority
AR
Argentina
Prior art keywords
spike protein
subject
subunit
modified
avian coronavirus
Prior art date
Application number
ARP200101291A
Other languages
English (en)
Inventor
Annika Kraemer-Kuehl
Thomas Min Stephan
Hans-Christian Philipp
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR122262A1 publication Critical patent/AR122262A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una proteína de espícula de coronavirus aviar o fragmento de esta, caracterizada porque al menos una parte de la subunidad S1 pertenece a un coronavirus aviar con un tropismo celular o tisular restringido, y en donde en la posición de aminoácido 267 se encuentra una cisteína. Reivindicación 19: Un coronavirus aviar caracterizado porque comprende la proteína de espícula o fragmento de esta de acuerdo con cualquiera de las reivindicaciones 1 a 14 o un IBV (virus de la bronquitis infecciosa) que comprende la proteína de espícula de acuerdo con cualquiera de las reivindicaciones 3 a 14. Reivindicación 28: Un método para reducir la ciliostasis en un sujeto que lo necesita, en comparación con un sujeto de un grupo de control no inmunizado de la misma especie, caracterizado porque el método comprende administrar al sujeto una cantidad terapéuticamente eficaz de una composición inmunógena de acuerdo con la reivindicación 22.
ARP200101291A 2019-05-10 2020-05-06 Subunidad s1 modificada de la proteína de espícula de coronavirus AR122262A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173821 2019-05-10

Publications (1)

Publication Number Publication Date
AR122262A1 true AR122262A1 (es) 2022-08-31

Family

ID=66554148

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101291A AR122262A1 (es) 2019-05-10 2020-05-06 Subunidad s1 modificada de la proteína de espícula de coronavirus

Country Status (1)

Country Link
AR (1) AR122262A1 (es)

Similar Documents

Publication Publication Date Title
ES2505695T3 (es) Composiciones inmunógenas para Streptococcus pyogenes
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
BRPI0607097B8 (pt) uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus
BRPI1015917A2 (pt) antígenos de rsv recombinantes.
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
CO2021014778A2 (es) Subunidad s1 modificada de la proteína de espícula de coronavirus
PE20191492A1 (es) Composicion farmaceutica que comprende selexipag
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
AR056133A1 (es) Virus de influenza canina y composiciones relacionadas y metodos de uso
WO2021216743A3 (en) Coronavirus vaccines, compositions, and methods related thereto
BR112022004058A2 (pt) Conjugados, populações de conjugados, composição farmacêutica, métodos para o tratamento de um sujeito com uma infecção viral, o tratamento profilático de uma infecção viral, para prevenir uma infecção secundária e para tratar ou prevenir uma infecção viral
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
BR112022024149A2 (pt) Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
WO2022150654A3 (en) Antigen-binding polypeptides specific for coronaviruses and uses thereof
EA200702079A1 (ru) Вакцина
AR122262A1 (es) Subunidad s1 modificada de la proteína de espícula de coronavirus
CO2021005069A2 (es) Vacuna de ibv h52 con proteína espicular heteróloga
BR112022021423A2 (pt) Uso de proteína surfactante d para tratar infecções virais
BR112022007776A2 (pt) Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína
BR112022016492A2 (pt) Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2
BR112022018822A2 (pt) Proteínas de pontos de coronavírus haptenizados
WO2023031306A3 (en) New coronavirus vaccine and method for designing and obtaining a virus vaccine